Related Experiment Video
Updated: Jul 15, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
Body mass index and mortality in patients with idiopathic pulmonary fibrosis
Mazen Alakhras1, Paul A Decker, Hassan F Nadrous
1Division of Pulmonary and Critical Care Medicine, Desk East 18, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Background:
To examine the relationship between body mass index (BMI) and mortality in patients with idiopathic pulmonary fibrosis (IPF).
Methods:
We studied a cohort of patients with IPF who were seen at the Mayo Clinic Rochester from 1994 through 1996. These patients met the current consensus definition of IPF. We excluded patients who had received prior treatment for IPF, had no follow-up data, or had no pulmonary function results available at the index visit.
Results:
Of the 197 patients fulfilling the inclusion criteria, the mean (+/- SD) age was 71.4 +/- 8.9 years, 137 patients (70%) were men, and the mean BMI was 28.2 +/- 4.6. These patients were categorized by BMI into the following three groups: < 25; 25 to 30; and >/= 30. There were 46 patients (23%) with a BMI of < 25 who had a median survival time of 3.6 years (1-year survival rate, 76% [95% confidence interval (CI), 65 to 90%]; 3-year survival rate, 54% [95% CI, 41 to 70%]). The second group consisted of 85 patients (43%) with a BMI between 25 and 30 who had a median survival time of 3.8 years (1-year survival rate, 84% [95% CI, 76 to 92%]; 3-year survival rate, 58% [95% CI, 48 to 70%]). The final group consisted of 66 patients (34%) with a BMI of >/= 30 and who had a median survival time of 5.8 years (1-year survival rate, 91% [95% CI, 84 to 98%]; 3-year survival rate, 69% [95% CI, 58 to 81%]). Using a proportional hazards regression model, survival was significantly associated with BMI (hazard ratio, 0.93 for each 1-U increase in BMI; 95% CI, 0.89 to 0.97; p = 0.002) with increased BMI being associated with better survival.
Conclusion:
Higher BMI was associated with better survival in patients with IPF.
Related Concept Videos
Drug Dosing: Obese Patients
Physical Assessment of the Respiratory Tract II: Palpation
Thoracic Palpation
Thoracic palpation detects tenderness, masses, lesions, respiratory excursions, and vocal fremitus. The nurse assesses...
Pulmonary Function Tests
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...